Literature DB >> 9065991

Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study).

J Mateo1, A Oliver, M Borrell, N Sala, J Fontcuberta.   

Abstract

Previous studies on the prevalence of biological abnormalities causing venous thrombosis and the clinical characteristics of thrombotic patients are conflicting. We conducted a prospective study on 2.132 consecutive evaluable patients with venous thromboembolism to determine the prevalence of biological causes. Antithrombin, protein C, protein S, plasminogen and heparin cofactor-II deficiencies, dysfibrinogenemia, lupus anticoagulant and antiphospholipid antibodies were investigated. The risk of any of these alterations in patients with familial, recurrent, spontaneous or juvenile venous thrombosis was assessed. The overall prevalence of protein deficiencies was 12.85% (274/2,132) and antiphospholipid antibodies were found in 4.08% (87/2,132). Ten patients (0.47%) had antithrombin deficiency, 68 (3.19%) protein C deficiency, 155 (7.27%) protein S deficiency, 16 (0.75%) plasminogen deficiency, 8 (0.38%) heparin cofactor-II deficiency and 1 had dysfibrinogenemia. Combined deficiencies were found in 16 cases (0.75%). A protein deficiency was found in 69 of 303 (22.8%) patients with a family history of thrombosis and in 205/1,829 (11.2%) without a history (crude odds ratio 2.34, 95% CI 1.72-3.17); in 119/665 (17.9%) patients with thrombosis before the age of 45 and 153/1,425 (10.7%) after the age of 45 (crude odds ratio 1.81, 95% CI 1.40-2.35); in 103/616 (16.7%) with spontaneous thrombosis and in 171/1,516 (11.3%) with secondary thrombosis (crude odds ratio 1.58, 95% CI 1.21-2.06); in 68/358 (19.0%) with recurrent thrombosis and in 206/1,774 (11.6%) with a single episode (crude odds ratio 1.78, 95% CI 1.32-2.41). Patients with combined clinical factors had a higher risk of carrying some deficiency. Biological causes of venous thrombosis can be identified in 16.93% of unselected patients. Family history of thrombosis, juvenile, spontaneous and recurrent thrombosis are the main clinical factors which enhance the risk of a deficiency. Laboratory evaluation of thrombotic patients is advisable, especially if some of these clinical factors are present.

Entities:  

Mesh:

Year:  1997        PMID: 9065991

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  27 in total

1.  Mini-gastric bypass in a patient homozygous for Factor V Leiden.

Authors:  Cesare Peraglie
Journal:  Obes Surg       Date:  2007-01       Impact factor: 4.129

2.  Quite a backup: pericardial varices in a patient with hereditary antithrombin deficiency.

Authors:  Jason N Salamon; Santhosh Mannem; Mark Guelfguat
Journal:  Quant Imaging Med Surg       Date:  2013-06

3.  More valid and reliable thrombophilia testing is required for predicting the recurrence and the required duration of treatment for venous thromboembolism.

Authors:  Utku Iltar
Journal:  J Thromb Thrombolysis       Date:  2018-11       Impact factor: 2.300

4.  Thrombophilia - how far and how much to investigate?

Authors:  R K Pinjala; L R C Reddy; R P Nihar; G V A Praveen; M Sandeep
Journal:  Indian J Surg       Date:  2012-01-13       Impact factor: 0.656

5.  Antithrombin III Utilization in a Large Teaching Hospital.

Authors:  Cristina M Salas; Marta A Miyares
Journal:  P T       Date:  2013-12

6.  Recurrent intra-cardiac thrombosis-A unique presentation of prothrombin G20210 mutation.

Authors:  Kartika Shetty; Nirmal Sunkara; Chowdhury Ahsan
Journal:  J Cardiol Cases       Date:  2011-03-09

Review 7.  Thrombophilia in pregnancy.

Authors:  I D Walker
Journal:  J Clin Pathol       Date:  2000-08       Impact factor: 3.411

8.  Thrombophilic screening in Turner syndrome.

Authors:  V Calcaterra; G Gamba; N Montani; A de Silvestri; V Terulla; G Lanati; D Larizza
Journal:  J Endocrinol Invest       Date:  2011-05-17       Impact factor: 4.256

Review 9.  Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options.

Authors:  Peter S Maclean; R Campbell Tait
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Bilateral cavo-ilio-femoral thrombosis in an adolescent with transient anti-phospholipid antibodies and factor V heterozygous mutation: a case report.

Authors:  Giulio Frontino; Arianna Passoni; Maria Antonietta Piscopo; Elena Grechi; Bruna Cammarata; Gabriella Pozzobon
Journal:  Cases J       Date:  2009-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.